甲状腺自身抗体预测妊娠期糖尿病患者自身免疫性甲状腺疾病的临床应用价值

在妊娠期糖尿病合并自身免疫性甲状腺疾病患者的预测过程中应用甲状腺自身抗体检测,探析其临床应用价值。本次探究中选取我院在2015年1月~2017年3月期间所收治的120例妊娠期糖尿病合并自身免疫性甲状腺疾病产妇作为研究组,另选取同期收治的120例健康产妇作为对照组,将两组产妇各项临床检测指标进行对比分析。研究组患者TSH(促甲状腺素)、T3(三碘甲状腺原氨酸)、T4(甲状腺素)、FT3(游离三碘甲状腺原氨酸)对比对照组患者而言不存在统计学意义(P0.05);研究组患者FT4(游离甲状腺素)、TGAb(抗甲状腺球蛋白抗体)、TPOAb(抗甲状腺过氧化物酶抗体)以及二者联合检测阳性率均显著性更优,对比对照组患者而言,差异存在统计学意义(P0.05)。在妊娠期糖尿病合并自身免疫性甲状腺疾病患者的预测过程中应用甲状腺自身抗体检测的临床应用价值较高,有利于及时发现甲状腺病变以及改善患者不良妊娠结局,值得临床借鉴。     

血清TGAb、TPOAb检测在甲状腺疾病中的诊断意义

甲状腺球蛋白抗体（TGAb）是主要的特异性甲状腺自身抗体,是甲状腺上皮细胞分泌的糖蛋白。甲状腺过氧化物酶抗体（TPOAb）是自身免疫性甲状腺疾病（antoimmune thyroid disease,AITD）的一种重要自身抗体,是慢性淋巴细胞性甲状腺炎的特异性诊断指标。     

甲状腺乳头状癌合并慢性淋巴细胞性甲状腺炎的临床病理特征分析

目的 探讨甲状腺乳头状癌(PTC)合并慢性淋巴细胞性甲状腺炎(CLT)的临床病理特征。方法 选择2017年3月至2020年5月许昌市中心医院收治的200例PTC合并CLT患者(PTC合并CLT组)、210例单纯PTC患者(单纯PTC组)的临床资料,比较两组患者的一般资料、超声特征、甲状腺功能指标及病理特征方面的差异。结果 与男性患者比较,女性患者PTC合并CLT发生比例较高,PTC合并CLT组促甲状腺激素、甲状腺球蛋白抗体(TG-Ab)和甲状腺过氧化物酶抗体(TPO-Ab)水平与单纯PTC组比较明显升高,多灶癌的比例亦高于单纯PTC组(P 0. 05)。结论 PTC合并CLT好发于女性,且该病常见多灶癌,且患者血清TSH、TG-Ab及TPO-Ab水平升高。     

高密度脂蛋白胆固醇水平与甲状腺自身免疫状况的相关性研究

目的 探讨中老年人群血清甲状腺球蛋白抗体(TgAb)及甲状腺过氧化物酶抗体(TPOAb)与高密度脂蛋白胆固醇(HDL-C)水平的相关性.方法 纳入1348名社区人员作为研究对象,根据HDL-C水平的不同将其分为＜1.26 mmol/L组、1.26～＜1.53 mmol/L组和≥1.53 mmoL/L组,分析3组基线特征...     

抗甲状腺球蛋白抗体及抗甲状腺过氧化物酶抗体检测自身免疫性甲状腺疾病的临床意义

目的观察抗甲状腺球蛋白抗体（A-TG）、抗甲状腺过氧化物酶抗体（A-TPO）在自身免疫性甲状腺疾病中的临床意义。方法采用罗氏Elecsys 2010电化学发光检测分析仪,对148例甲状腺疾病患者进行A-TG、A-TPO、T3、T4、FT3、FT4、TSH的平行检测。结果自身免疫性甲状腺疾病（Graves病、桥本氏甲状腺炎、原发性甲减）A-TG、A—TPO含量均明显高于结节性甲状腺肿和单纯性甲状腺肿,阳性率分别达到63％、81％、65％,差异有统计学意义。结论A—TG、A—TP0在诊断自身免疫性甲状腺疾病和非自身免疫性甲状腺疾病中具有重要的临床意义,结合临床症状可帮助鉴别诊断各类甲状腺疾病。     

自身免疫甲状腺炎的诊断和治疗

1 引言 自身免疫甲状腺炎（Autoimmune thyroiditis,AIT）是一组由自身免疫功能紊乱引起的甲状腺疾病,临床包括慢性淋巴细胞性甲状腺炎（桥本甲状腺炎）、萎缩型甲状腺炎、无痛性甲状腺炎和产后甲状腺炎等,其共同的病理生理基础是自身免疫反应引起的甲状腺结构和（或）功能的异常。     

甲状腺自身抗体在自身免疫性甲状腺疾病诊断中的应用价值

目的 探究甲状腺自身抗体在自身免疫性甲状腺疾病(AITD)诊断中的应用价值.方法 选择2019年5月至2020年5月我院收治的80例AITD患者作为AITD组,其中34例为桥本甲状腺炎(HT),46例为毒性弥漫性甲状腺肿(Graves病);另选取同期我院50例健康体检者作为对照组.比较各组的促甲状腺激素受体抗体(TRA...     

2型糖尿病患者甲状腺自身免疫抗体阳性率分析

糖尿病与甲状腺疾病是内分泌代谢系统疾病中最常见的两大类疾病,二者密切相关。2型糖尿病是一种炎症性疾病,其发病机制也与免疫有关。在临床实践中也常见到糖尿病合并自身免疫甲状腺病的患者。故近年来针对糖尿病合并甲状腺疾病的研究日渐深人     

TGAb联合TPOAb用于妊娠期自身免疫性甲状腺疾病筛查的临床价值

目的 探讨甲状腺球蛋白抗体(TGAb)联合甲状腺过氧化物酶抗体(TPOAb)用于妊娠期自身免疫性甲状腺疾病(AITDs)筛查的临床价值。方法 随机选取在该院进行孕检的妊娠妇女300例作为孕期组,其中包含孕早期、孕中期和孕晚期妇女各100例,另选取同期非妊娠期健康妇女100例作为对照组。检测研究对象血清促甲状腺激素(TSH)、游离甲状腺素(FT₄)、TGAb和TPOAb水平,比较两组甲状腺疾病发病率,绘制受试者工作特征曲线分析TGAb和TPOAb诊断AITDs的价值,采用直线回归分析TGAb和TPOAb的相关性。结果 孕期组的甲状腺疾病的总发病率(17.00%)高于对照组(13.00%),在所有研究对象中以亚临床甲状腺功能减退和单纯抗体阳性的发病率最高,分别为7.50%和3.50%。TGAb诊断AITDs的曲线下面积(AUC)为0.778,TPOAb诊断AITDs的AUC为0.895,二者联合检测的AUC为0.985。TGAb和TPOAb不具有线性相关性。结论 TGAb和TPOAb在AITDs的诊疗过程中不可相互替代,且通过联合检测可以提高其对于AITDs的诊断价值...     

自身免疫性甲状腺疾病肾损害临床分析

自身免疫性甲状腺疾病 (ＡｕｔｏｉｎｎｕｎｅＴｈｙｒｏｉｄＤｉｓｅａｓｅ,ＡＩＴＤ）包括Ｇｒａｖｅｓ病、甲状腺炎和甲状腺机能减退症 (甲减 )。ＡＩＴＤ与肾损害的关系近年来已引起临床的重视 ,但其机理及相关因素目前尚不完全清楚 ,本病早期诊治 ,预后良好 ,现将笔者所见４例报道如下。临床资料１、一般资料１９９９年６月至２０００年５月 ,本院收住４例 ,Ｇｒａｖｅｓ病３例 ,甲状腺机能减退１例。男性２例 ,女性２例。年龄３９～４４岁。２、临床表现３例Ｇｒａｖｅｓ病患者均有不同程度血压增高 (１５０～１８０／９４～１０５ｍ…     

Measurement of anti-thyroglobulin IgG in urine of patients with autoimmune thyroid diseases by sensitive enzyme immunoassay (immune complex transfer enzyme immunoassay)

Anti-thyroglobulin IgG in urine of patients with Graves' disease and chronic thyroiditis and healthy subjects was measured by a sensitive enzyme immunoassay (immune complex transfer enzyme immunoassay). Anti-thyroglobulin IgG in dialyzed urine was reacted simultaneously with 2,4-dinitrophenylated thyroglobulin and thyroglobulin-βT-D -galactosidase conjugate. The immune complex formed consisting of the three components was trapped onto polystyrene balls coated with (anti-2,4, dinitrophenyl group) IgG, eluted with ∈N-2,4-dinitrophenyl-L-lysine, and transferred onto polystyrene balls coated with (antihuman IgG γ-chain) IgG. β-D -Galactosidase activity bound to the last polystyrene balls was assayed by fluorometry. Anti-thyroglobulin IgG was detected in most of the patients, but not in most of the healthy subjects; levels of anti-thyroglobulin IgG in urine of the patients were well correlated to those in serum of the same patients. The measurement of anti-thyroglobulin IgG in urine by the immune complex transfer enzyme immunoassay was suggested to be useful as a diagnostic aid for autoimmune thyroid diseases. The conventional standard ELISA was not sufficiently sensitive for measuring anti-thyroglobulin IgG in urine. © 1993 Wiley-Liss, Inc.     

Improved measurement of anti-thyroglobulin IgG in urine of patients with autoimmune thyroid diseases by sensitive enzyme immunoassay (immune complex transfer enzyme immunoassay)

Previously, antithyroglobulin IgG was assayed in dialyzed urine from patients with autoimmune thyroid diseases by a sensitive enzyme immunoassay (immune complex transfer enzyme immunoassay), and most of the assay results were useful as a diagnostic aid for autoimmune thyroid diseases. However, dialysis of urine was laborious and time-consuming, and some results were less reliable due to low levels of anti-thyroglobulin IgG in urine. This paper describes some improvements of the assay. Useful assay results could be obtained for most of urine samples without dialysis, although some interfering substance(s) was suggested to be present in some urine samples before dialysis. Accurate assay results with no interference could be obtained after gel filtration by only two min centrifugation in place of dialysis. More reliable assay results for urine samples containing low levels of antithyroglobulin IgG were obtained after concentration using a molecular sieve. © 1993 Wiley-Liss, Inc.     

Correlation of computerized gray-scale sonographic findings with thyroid function and thyroid autoimmune activity in patients with Hashimoto's thyroiditis

PURPOSE: The objective of this study was to retrospectively assess whether computerized gray-scale sonography can allow objective measurement of thyroid echogenicity in patients with Hashimoto's thyroiditis (HT) at various functional stages of the disease. METHODS: Of the 77 patients with HT who were included in our study, 28 had been euthyroid, 20 had had subclinical hypothyroidism, and 29 had had clinical hypothyroidism. Of those with clinical hypothyroidism, 6 had been untreated and 23 had been receiving L-thyroxine substitution therapy. Fifty volunteers without thyroid disease served as a control group. Thyroid echogenicity was evaluated by computerized gray-scale sonography as mean tissue density (MTD) +/- standard deviation; the echogenicity of the prethyroid muscles served as a control of the system variability. RESULTS: The MTD was significantly lower for the patients with HT (15.9 +/- 4) than for the control subjects (24.3 +/- 3; p < 0.05). Moreover, a significant difference was found between the MTD values of euthyroid patients with HT (18.9 +/- 3.4) and hypothyroid patients with HT analyzed either as a group (14.3 +/- 3.8) or separately for subclinical hypothyroidism (14.9 +/- 3.8) and clinical hypothyroidism (13.9 +/- 3.7; p < 0.05). The lowest MTD was found in patients with untreated clinical hypothyroidism (11.1 +/- 4.3), with a significant difference (p < 0.05) compared to all other groups of patients. Untreated patients with clinical hypothyroidism also showed the highest mean anti-thyroid peroxidase autoantibody levels (1,286 +/- 177 IU/ml versus 570 +/- 489 IU/ml for L-thyroxine-treated patients; p < 0.05), although no correlation between the MTD values and anti-thyroid peroxidase autoantibody levels was found in any group of patients. CONCLUSIONS: Computerized gray-scale sonography provides an objective measure of thyroid hypoechogenicity, which correlates well to the clinical stages of HT. Use of this modality may prove beneficial in the diagnosis and follow-up of patients with HT.     

妊娠期糖尿病高危孕妇甲状腺功能及甲状腺自身抗体变化的研究

目的探讨妊娠期糖尿病高危孕妇的甲状腺功能及甲状腺自身抗体的变化。方法依据糖耐量试验结果,选取135例妊娠期糖尿病高危孕妇作为研究组（包括正常糖耐量组、妊娠期糖耐量受损组及妊娠期糖尿病组）,30例无糖尿病高危因素的健康孕妇做为对照组。采用化学发光法检测各组血清中抗甲状腺球蛋白抗体、抗甲状腺过氧化物酶抗体、三碘甲状腺原氨酸（T3）、甲状腺素（T4）、游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）、促甲状腺素（TSH）含量。结果妊娠期糖尿病孕妇组FT4低于健康孕妇组（P〈0.01）、正常糖耐量组（P〈0.01）及妊娠期糖耐量受损组（P〈0.05）。在135名妊娠期糖尿病高危孕妇中有23名甲状腺自身抗体阳性（17%）,其中有糖尿病及甲状腺家族史的孕妇甲状腺自身抗体阳性率（38.9%）明显高于没有家族史的孕妇（11.1%）（P〈0.01）。结论在妊娠期糖尿病高危孕妇中进行甲状腺自身抗体的筛查及甲状腺功能评估有着重要意义。     

乙型糖尿病患者甲状腺激素及自身抗体异常的临床分析

目的：通过分析乙型糖尿病患者和健康对照组甲状腺激素及自身抗体的异常情况,探讨乙型糖尿病和甲状腺疾病的关系。方法对396例乙型糖尿病患者及411例健康体检者（对照组）测定其血清促甲状腺激素（TSH）、游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）水平,同时测定其抗甲状腺球蛋白抗体（TGAb）及抗甲状腺过氧化物酶抗体（TPOAb）。结果在健康对照组中,甲状腺激素异常发病率为7．5％,其中男性为5．5％,女性为9．4％,女性亚甲减患病率为4．7％,高于男性亚甲减患病率的1．5％,差异有统计学意义（P ＜0．05）;健康对照组中 TPOAb 阳性率为10．2％,TGAb 阳性率为6．6％。在乙型糖尿病（T2DM）患者中,甲状腺激素异常发病率为16．2％,男性为12．3％,女性为20．5％,其中女性亚甲减患病率为9．2％高于男性4．3％,差异有统计学意义（P ＜0．01）,T2DM 患者亚甲减占甲状腺功能异常发生率的40．6％;TPOAb 阳性率为15．2％,TGAb阳性率为7．1％。结论乙型糖尿病患者中甲状腺疾病患病率较健康对照组明显增加,以女性亚甲减为主;对糖尿病患者进行甲状腺自身抗体筛查及定期监测 FT3、FT4、TSH,对糖尿病患者的病情的评估、预后的判断和指导治疗具有重要的临床意义。     

桥本甲状腺炎合并甲状腺癌的临床病理研究

目的:探讨桥本甲状腺炎(HT)与甲状腺乳头状癌(PTC)的关系。方法:单纯HT73例,HT合并PTC23例,分析两者的临床表现、病理组织学表现,并作酪氨酸激酶受体(RET)免疫组化染色。结果:HT临床表现多样化,部分表现为结节状,合并的甲状腺癌均为乳头状癌,且微小癌占多数。50%HT病变对于RET染色存在局灶性阳性反应。结论:HT病变组织中不同程度地存在与PTC相同的肿瘤基因,HT合并的PTC可能与HT有关。     

Biological variability of thyroid autoantibodies (anti-TPO and anti-Tg) in clinically and biochemically stable patients with autoimmune thyroid disease

The biological variation of anti-TPO and anti-Tg autoantibodies was studied in 17 clinically and biochemically stable female patients with autoimmune thyroid disease (AITD), at regular monthly intervals over a period of 6 consecutive months. The mean and standard deviation (SD), within-subject coefficient of variation (CV), between-subject CV, index of individuality, reliability coefficient, and critical differences were as follows: for anti-TPO 238 (197) U/ml, 9.2%, 81.4%, 0.11, 0.96, and 27.6%; and for anti-Tg 1,785 (3,170) U/ml, 6.9%, 174%, 0.04, 0.99, and 22.3%. The data indicate a low within-subject CV, and a high between-subject CV that is particularly pronounced for anti-Tg. The high individuality of both autoantibodies indicates that an isolated result compared to conventional population-based reference intervals is of very little value for diagnosis. Furthermore, the near to 1 reliability coefficient for both autoantibodies correctly classifies the patient with respect to his or her homeostatic mean antibody concentration in a 6-month period of clinical and biochemical stability of thyroid disease. Imprecision goals for anti-TPO and anti-Tg antibodies are attainable with current methodology.